Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI) is expected to be issuing its results after the market closes on Tuesday, May 19th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.

Greenwich LifeSciences Stock Performance

NASDAQ:GLSI opened at $24.13 on Tuesday. The firm has a market cap of $334.20 million, a PE ratio of -16.53 and a beta of 1.39. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $34.10. The business has a 50 day moving average price of $24.92 and a 200-day moving average price of $20.13.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Greenwich LifeSciences has an average rating of “Hold” and a consensus price target of $47.50.

Hedge Funds Weigh In On Greenwich LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio bought a new position in shares of Greenwich LifeSciences during the first quarter valued at approximately $177,000. Barclays PLC raised its holdings in shares of Greenwich LifeSciences by 11.8% during the fourth quarter. Barclays PLC now owns 9,744 shares of the company’s stock valued at $205,000 after acquiring an additional 1,030 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Greenwich LifeSciences by 52.1% during the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock valued at $208,000 after acquiring an additional 7,174 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Greenwich LifeSciences during the fourth quarter valued at approximately $217,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Greenwich LifeSciences by 8.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 21,545 shares of the company’s stock valued at $453,000 after acquiring an additional 1,700 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.